
Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer
Kim, Richard D., McDonough, Shannon, El-Khoueiry, Anthony B., Bekaii-Saab, Tanios S., Stein, Stacey M., Sahai, Vaibhav, Keogh, George P., Kim, Edward J., Baron, Ari D., Siegel, Abby B., Barzi, AfsanehVolume:
130
Journal:
European Journal of Cancer
DOI:
10.1016/j.ejca.2020.01.026
Date:
May, 2020
Fichier:
PDF, 700 KB
2020